Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 4, 2003, Pages 288-292

  Suzuki, Eiji ^a   Nakaki, Toshio ^b   Nakamura, Makoto ^c   Miyaoka, Hitoshi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Nitric oxide; Nitric oxide synthase; Schizophrenia; Signs and symptoms

Indexed keywords

NITRATE; NITRIC OXIDE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MALE; NEUROLOGIC DISEASE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; NITRATES; NITRIC OXIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0141678875     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991;14:60-7.
2. Schmidt HH, Walter U. NO at work. Cell 1994;78:919-25.
3. Zhu XZ, Luo LG. Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices. J Neurochem 1992;59:932-5.
4. Lorrain DS, Hull EM. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. Neuroreport 1993;5:87-9.
5. 3H]dopamine uptake. Brain Res 1994;641:83-91.
6. Pögün S, Kuhar MJ. Regulation of neurotransmitter reuptake by nitric oxide. Ann N Y Acad Sci 1994;17:305-15.
7. Seilicovich A, Lasaga M, Befumo M, Duvilanski BH, del Carman Diaz M, Rettori V, et al. Nitric oxide inhibits the release of norepinephrine and dopamine from the medial hypothalamus of the rat. Proc Natl Acad Sci U S A 1995;92:11299-302.
8. O'Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, Kandel ER, et al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science 1994;265:542-6.
9. Salemme E, Diano S, Maharajan P, Maharajan V. Nitric oxide, a neuronal messenger. Its role in the hippocampus neuronal plasticity. Riv Biol 1996;89:87-107.
10. Kleppisch T, Pfeifer A, Klatt P, Montowski A, Fassler R, Hofmann F. Long-term potentiation in the hippocampal CA1 region of mice lacking cGMP-dependent kinases is normal and susceptible to inhibition of nitric oxide synthase. J Neurosci 1999;19:48-55.
11. Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbance of cortical development. Arch Gen Psychiatry 1993;50:169-77.
12. Akbarian S, Viñuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-87.
13. Karson CN, Griffin WST, Mark RE, Husain M, Dawson TM, Snyder SH, et al. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol 1996;27:275-84.
14. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 1995;212:375-80.
15. Herken H, Uz E, Özyurt H, Akyol Ö. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 2001;52:289-90.
16. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HSV, Sucher NJ, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993;364:626-32.
17. Nakaki T, Mishima A, Fujii T, Suzuki E, Shintani F. Nitric oxide and neurodegenerative diseases. Curr Top Pulm Pharmacol Toxicol 1997;3:157-63.
18. Strauss JS, Carpenter WT, Bartko JJ. An approach to the diagnosis and understanding of schizophrenia: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974;1:61-9.
19. Crow TJ. Molecular pathology of schizophrenia: more than one dimension of pathology? BMJ 1980;280:66-8.
20. Owens DGC, Johnstone EC. The disabilities of schizophrenia: their nature and the factors contributing to their development. Br J Psychiatry 1980;136:384-95.
21. Owens DGC, Johnstone EC, Crow TJ, Firth CD, Jagoe JR, Kreel L. Cerebral ventricular enlargement in schizophrenia: relationship to the disease process and its clinical correlates. Psychol Med 1985;15:27-41.
22. Carpenter WT, Heinrichs DW, Wagman AM. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-83.
23. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30:119-23.
24. Keefe RSE, Mohs RC, Davidson M, Losonczy MF, Silverman JM, Lesser JC, et al. Kraepelinian schizophrenia: a subgroup of schizophrenia? Psychopharmacol Bull 1988;24:56-61.
25. Keefe RSE, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, et al. Diagnostic issues in chronic schizophrenia: Kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophr Res 1991;4:71-9.
26. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
27. Suzuki E, Kanba S, Nibuya M, Inada T, Sekiya U, Ashikari I, et al. The schedule for the deficit syndrome and reliability of the Japanese version [In Japanese]. Seishin Igaku Kenkyusho Gyosekishu 1993;35:1097-103.
28. Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinoshita N, et al. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 1995;38:50-6.
29. Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT Jr. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry 1994;51:804-11.
30. Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT Jr. Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry 1997;154:363-70.
31. Bustillo JR, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT Jr. Visual information processing impairments in deficit and nondeficit schizophrenia. Am J Psychiatry 1997;154:647-54.
32. Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, et al. Structural abnormalities in deficit and non-deficit schizophrenia. Am J Psychiatry 1993;150:59-65.
33. Tamminga CA, Thaler GK, Buchanan RW, Kirkpatrick B, Alphs LD, Chase TN, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-30.
34. Suzuki E, Kanba S, Koshikawa H, Nibuya M, Yagi G, Asai M. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations. J Psychiatry Neurosci 1996;21:167-71.
35. Gainetdinov RP, Mohn AR, Caron MG. Genetic models: focus on schizophrenia. Trends Neurosci 2001;24:527-33.
36. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behavior, stereotyped behavior, and locomotor activity in rats. Neuropsychoharmacology 1998;19:18-25.
37. Föstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 1995;352:351-64.
38. Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989;172:413-6.
39. Osawa Y, Davila JC. Phencyclidine, a psychotomimetic agent and drug abuse, is a suicide inhibitor of brain nitric oxide synthase. Biochem Biophys Res Commun 1993;194:1435-9.
40. Bird DC, Bujas-Bobanovic M, Robertson HA, Dursun SM. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology 2001;155:299-309.
41. Bujas-Bobanovic M, Bird DC, Robertson HA, Durson SM. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 2000;130:1005-12.
42. Bujas-Bobanovic M, Robertson HA, Dursun SM. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencyclidine-induced effects in rats. Eur J Pharmacol 2000;409:57-65.
43. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 2001;158:140-5.
44. Shinkai T, Ohmori O, Hori H, Nakamura J. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry 2002;7:560-3.
45. Suzuki E, Nakaki T, Shintani F, Kanba S, Miyaoka H. Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain. Neurosci Lett 2002;333:217-9.
46. Das I, Kahn NS, Puri BK, Hirsch SR. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett 1996;215:209-11.
47. Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001;63:221-4.